Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7797]

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

ASCO 2015: Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

ASCO 2015: Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

ASCO 2015: Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

ASCO 2015: Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

ASCO 2015: Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

Deadly ovarian cancer outsmarts chemotherapy

Deadly ovarian cancer outsmarts chemotherapy

Opening LOX to bone metastasis of breast cancer

Opening LOX to bone metastasis of breast cancer

How ovarian cancers evade chemotherapy

How ovarian cancers evade chemotherapy

ASCO 2015: Adding chemotherapy to initial therapy extends lives of men with advanced, hormone-naïve prostate cancer

ASCO 2015: Adding chemotherapy to initial therapy extends lives of men with advanced, hormone-naïve prostate cancer

ASCO 2015: Simple oral vitamin reduces risk of common, non-melanoma skin cancers

ASCO 2015: Simple oral vitamin reduces risk of common, non-melanoma skin cancers

Positive CHMP opinion recommends ibrutinib for the treatment of Waldenström’s macroglobulinemia

Positive CHMP opinion recommends ibrutinib for the treatment of Waldenström’s macroglobulinemia

More from ecancer